A Multicenter, International, Prospective, Non-interventional, Observational Study, to Assess Treatment Retention of an Adalimumab Biosimilar (Hyrimoz®) in IBD Patients in Real Life Setting
Latest Information Update: 05 Dec 2024
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Therapeutic Use
- Acronyms HYRISS
- Sponsors Sandoz
- 07 May 2024 Planned End Date changed from 15 Dec 2025 to 1 Dec 2026.
- 21 Apr 2023 Status changed from not yet recruiting to recruiting.
- 03 Feb 2023 Planned End Date changed from 2 Nov 2026 to 15 Dec 2025.